<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tblu9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>LM-4175 only, LM-4175 + Cav1 WT pMEFs, LM-4175 + Cav1 KO pMEFs</td><td>0.504525<xref ref-type="table-fn" rid="tblfn2">*</xref></td><td>80.0%<xref ref-type="table-fn" rid="tblfn2">*</xref></td><td>41<xref ref-type="table-fn" rid="tblfn3">&#8224;</xref> (3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>*</label><p>A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with the sample size reported and 80% power.</p></fn><fn id="tblfn3"><label>&#8224;</label><p>Since the non-parametric Kruskal&#8211;Wallis test will be performed for the analysis instead of an ANOVA, the sensitivity calculation was performed with a &#8764;15% adjustment in sample size to calculate the effect size that can be detected with 80% power. The total sample size of 49, which comes from the total metastatic foci per mouse sample size calculation, was reduced by &#8764;15%&#8211;41 for this calculation to estimate the detectable effect size.</p></fn></table-wrap-foot></table-wrap>